RECRUITING Not applicable ClinicalTrials.gov

Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses

Sponsor: Montefiore Medical Center • ClinicalTrials.gov ID: NCT07631598

Registry updated: 2026-10-01

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms. The study compares two ways of connecting people to treatment: Referral to a community treatment provider (usual care before the new program begins). Onsite, low-threshold buprenorphine treatment at the SSP, which allows participants to start medication quickly and without having to establish care at another provider. Participants will be adults who have opioid use disorder and are SSP clients. Each SSP will begin offering the new onsite buprenorphine program at different times during the study. Researchers will collect information before and after the new program begins to see how it affects treatment engagement and health outcomes. The study will also examine how easy or difficult it is for SSPs to start and run the new program, how acceptable it is to staff and participants, and whether it is cost-effective. The overall goal is to find better ways to expand access to life-saving opioid treatment in community-based settings.

Interventions

Standard of Care Referral (Other)
During the pre-implementation phase, SSP staff will refer participants with opioid use disorder to external community providers for buprenorphine treatment. Services offered include information, referral assistance, and linkage to care, but buprenorphine will not be initiated or managed at the SSP site.
Low Threshold Buprenorphine (Behavioral)
During the post-implementation phase, SSPs will implement a low-threshold model of care for buprenorphine treatment. This model includes: Low barrier to entry Flexible scheduling and follow-up procedures Risk reduction counseling Collaboration with a peer outreach worker Training and technical assistance for SSP staff and clinicians to deliver care in non-traditional, low-barrier settings This intervention focuses on implementing and evaluating a service delivery model to expand access to medication for opioid use disorder within SSPs.

Eligibility criteria

Inclusion Criteria: 1. ≥ 18 years old; 2. Meet DSM-5 criteria for moderate or severe OUD; 3. Interest in receiving buprenorphine treatment; 4. Speaks English or Spanish; 5. Currently an SSP client at the time of enrollment; 6. Ability to provide informed consent. Exclusion Criteria: 1. Current use of prescribed opioid agonist treatment, as assessed by self-report, at the time of enrollment; 2. Unstable mental health or medical condition that requires an immediate clinical evaluation or higher level of care; 3. Allergy to buprenorphine; 4. Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law. or have pending legal action that could prevent participation on study activities.

Conditions

Opioid Use Disorder Opioid Use Disorder, Severe Opioid Use Disorder, Moderate

Locations

Community Health Project Los Angeles (CHPLA) — Los Angeles, California, United States
HIPS — Washington D.C., District of Columbia, United States
CARPBR/Be Safe Syringe Program — Baton Rouge, Louisiana, United States
Harm Reduction Sisters — Duluth, Minnesota, United States
Alianza of New Mexico — Roswell, New Mexico, United States
HIV Alliance — Grants Pass, Oregon, United States
Challenges, Inc/Prisma Health — Greenville, South Carolina, United States
Vivent Health — Milwaukee, Wisconsin, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment